Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Indivior Logo
Indivior Growth Score
81
CB Rank
86674
Heat Score
60
Indivior is a specialty pharmaceuticals business.
Founded
obfuscation
PublicPost-IPO Debt Richmond, Virginia, United States1001-5000 indivior.com/
Addiction Treatment
Biotechnology
Communities
Health Care
Medical
Pharmaceutical
Social
Overview

Indivior
Total Funding
obfuscation
Growth Score
81
Heat Score
60

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score81
-4 pts
in past quarter
Heat Score 60
-22 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Indivior

CB Rank
86674
Indivior is a specialty pharmaceuticals business.
Founded
obfuscation
PublicPost-IPO Debt Richmond, Virginia, United States1001-5000 indivior.com/
Addiction Treatment
Biotechnology
Communities
Health Care
Medical
Pharmaceutical
Social

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Indivior PLC
Operating Status Active
Number of Exits 
obfuscation
Stock Symbol  LSE:INDV
Company Type For Profit
About the Company

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated

chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Phone Number +1 804 379 1090
Contact Email cassie.france-kelly@indivior.com
Predictions & Insights

Growth Insight

See this Growth Insight
Indivior is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Subutex
A medication containing buprenorphine used to treat opioid dependence by reducing withdrawal symptoms and cravings.
Suboxone
A medication combining buprenorphine and naloxone to treat opioid dependence by reducing withdrawal symptoms and preventing misuse.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
obfuscation
— Post-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Piper Sandler Logo
Piper Sandler
Yes
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
Piper Sandler Logo
Piper Sandler
Yes
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
Piper Sandler Logo
Piper Sandler
Yes
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
Piper Sandler Logo
Piper Sandler
Yes
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—
Piper Sandler Logo
Piper Sandler
Yes
Post-IPO Debt - Indivior Logo
Post-IPO Debt - Indivior
—

Investments

Number of Investments 2
Number of Exits 
obfuscation
Number of Acquisitions 1
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation

Investment Breakdown

Number of Investments 2
Number of Exits 
obfuscation
Number of Acquisitions 1
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
obfuscation
Addex Therapeutics Logo
Addex Therapeutics
Yes
Post-IPO Equity - Addex Therapeutics Logo
Post-IPO Equity - Addex Therapeutics
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 1001-5000 Employee Profiles 9 Board Members and Advisors 2 Contacts 956

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 14, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

15,107
42.73%
 in past month

IT Spend

$25.5MThis year, Indivior is projected to spend $25.5M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Chargeback Logo
Chargeback
100
Cash Forecasting Logo
Cash Forecasting
100
Windows Operating System Logo
Windows Operating System
100

Actively Used Products

19Indivior uses 19 technology products and services including HTML5, jQuery, and  Office 365, according to G2 Stack.

Active Website Tech Count

55Indivior is actively using 55 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, Viewport Meta, and  SSL by Default.

Total IP

7The intellectual property of Indivior includes 3 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Indivior has registered 4 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Indivior's headquarters? Indivior is located in Richmond, Virginia, United States.Who invested in Indivior? Indivior has 2 investors including Piper Sandler and  Oaktree Capital Management.When was the last funding round for Indivior? Indivior closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Indivior's competitors? Alternatives and possible competitors to Indivior may include Collegium Pharmaceutical, Theravance Biopharma, and  Teva Pharmaceuticals.How much funding has Indivior raised to date? Indivior has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(2e7868f 1)
|